Ktao was founded with the primary aim of providing investors with access to Israel's best early-stage bio-convergence investment opportunities.

The firm identifies the right entrepreneurs and technologies to achieve the highest returns while helping humanity.

Ktao enables entrepreneurs to transition from research to market readiness through hands-on management and early-stage cooperation with prominent partners.

The Ktao team brings extensive experience in managing and growing early-stage companies, helping the portfolio companies to achieve a successful outcome.